InvestorsHub Logo

rafunrafun

12/07/18 6:21 AM

#165929 RE: Jt0082 #165928

Also for EPANOVA what happens when strength reads out? Amarin say two things:

1. Competition is good and it will build the class of omega 3s and build the market.

2. We have blocking IP that stops Epanova from coming to market


We already (currently) have #2, so STRENGTH wouldn't change anything, except the amount of money that AZN would be willing to give us.

BaaBaa45

12/07/18 6:56 AM

#165936 RE: Jt0082 #165928

JT had more faces than a town hall clock at that point.

He was addressing AZN as both a competitor and potential acquirer at the same time!!

L0tsaluck2000

12/07/18 7:02 AM

#165941 RE: Jt0082 #165928

The critical information need right now is to get the message out that L or generic L are not VASCEPA

Either that or tell me how to buy shares that leverage generic L sales.

HerbieRay

12/07/18 12:07 PM

#166055 RE: Jt0082 #165928

It's as if our competitors by the results of their trial that they cannot capitalize on, have done free advertising for us.

amarinbullfromchicago

12/07/18 4:19 PM

#166132 RE: Jt0082 #165928

At this point I don't see how we don't get a boost after STRENGTH is over.

comes back positive- we have patents, and more literature to Omega 3s. and AZN prob makes offer
comes back negative- AZN looks stupid and probably has to put in a bid for amarin/theres no competition in sight